Wave crashes on DMD data as investors await Huntington’s readout

Wave’s decision to discontinue its two Duchenne muscular dystrophy programs raised broader investor concerns about the company’s stereopure oligonucleotide platform and sent shares down more than 50% on Monday. Another readout for the platform in a second indication before year-end should provide more clues about the platform’s potential.

Wave Life Sciences Ltd. (NASDAQ:WVE) fell $20.81 (55%) to $16.79 on Monday after announcing that suvodirsen failed to change dystrophin levels in an interim analysis of a Phase I open label extension study in 36 DMD patients...